4//SEC Filing
Valle Franco 4
Accession 0000899243-21-003651
CIK 0001731831other
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 7:22 PM ET
Size
6.5 KB
Accession
0000899243-21-003651
Insider Transaction Report
Form 4
Valle Franco
Senior Vice President, Finance
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−24,350→ 0 totalExercise: $7.24Exp: 2028-05-06→ Common Stock (24,350 underlying)
Footnotes (2)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time").
- [F2](Continued From Footnote 1) The option vests over four years after March 28, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Documents
Issuer
Eidos Therapeutics, Inc.
CIK 0001731831
Entity typeother
Related Parties
1- filerCIK 0001699848
Filing Metadata
- Form type
- 4
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 7:22 PM ET
- Size
- 6.5 KB